CO5261604A1 - Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo - Google Patents

Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo

Info

Publication number
CO5261604A1
CO5261604A1 CO00077957A CO00077957A CO5261604A1 CO 5261604 A1 CO5261604 A1 CO 5261604A1 CO 00077957 A CO00077957 A CO 00077957A CO 00077957 A CO00077957 A CO 00077957A CO 5261604 A1 CO5261604 A1 CO 5261604A1
Authority
CO
Colombia
Prior art keywords
lower alkyl
alkoxy
alkyl
optionally substituted
lower alkoxy
Prior art date
Application number
CO00077957A
Other languages
English (en)
Inventor
Geo Adam
Alexander Alanine
Erwin Goetschi
Vincent Mutel
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5261604A1 publication Critical patent/CO5261604A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de fórmula general I <EMI FILE="00077957_1" ID="1" IMF=JPEG >en donde X es un enlace sencillo o un grupo etinodiílo, en donde, En caso de que X sea un enlace sencillo, R1 es halógeno o fenilo que está opcionalmente sustituido con halógeno, alquilo inferior, haloalquilo inferior, alcoxi inferior, halo-alcoxilo inferior, o ciano; En caso de que X sea un grupo etinodiílo, R1 es fenilo, opcionalmente sustituido con halógeno, alquilo inferior, halo-alquilo inferior, cicloalquilo inferior, alcoxilo inferior o halo-alcoxilo inferior; R2 es halógeno; hidroxilo; alquilo inferior; halo-alquilo inferior; alcoxilo inferior; hidroximetilo; hidroxietoxilo; alcoxilo inferior-(etoxi)n (n =1 a 4); alcoxilo inferior-metilo; cianometoxilo; morfolin-4-ilo; tiomorfolin-4-ilo; 1-oxotiomorfolin-4-ilo; 1,1-dioxotiomorfolin-4-ilo; 4-oxo-piperidin-1-ilo; 4-alcoxi-piperidin-1-ilo; 4-hidroxi-piperidin-1-ilo; 4-hidroxietoxi-piperidin-1-ilo; 4-alquilo inferior-piperazin-1-ilo; alcoxicarbonilo; 2-dialquilamino etilsulfanilo-; N,N-bis alquilamino inferior alquilo inferior; carbamoilmetilo; alquilsulfonilo; alcoxilo inferior-carbonil-alquilo inferior; alquilcarboxi-alquilo inferior; carboxi-alquilo inferior; alcoxicarbonilmetilsulfanilo; carboximetilsulfanilo; 1,4-dioxa-8-aza-espiro[4.5]dec-8-il; carboxi-alcoxilo inferior; ciano-alquilo inferior; 2,3-dihidroxi-alcoxilo inferior; carbamoilmetoxilo; 2-oxo-[1,3]-dioxolan-4-il-alcoxilo inferior; (2-hidroxi-alquilo inferior)-amino alquilo inferior; hidroxicarbamoil-alcoxiIo inferior; 2,2-dimetil-tetrahidro[1,3]dioxolo[4,5c]-pirrol-5-il; alcoxilo inferior-carbamoil-alcoxilo inferior; 3R-hidroxipirrolidin-1-il; 3,4-dihidroxi-pirrolidin-1-il; 2-oxo-oxazolidin-3-il; alquilo inferior carbamoilmetoxi; ó aminocarbamoil-alcoxilo inferior; - 2 -R3 es arilo o heteroarilo de 5 ó 6 eslabones que están opcionalmente sustituidos por halógeno; ciano; nitro; azido; hidroxilo; carboxilo; morfolin-4-carbonilo; carbamoílo; tiocarbamoílo; N-hidroxicarbamoílo; trimetilsilil-etinilo; ó alquilo inferior; alcoxilo inferior; halo-alquilo inferior; 4-alquilo inferior-piperazin-1-carbonilo; alquilo inferior carbamoílo que están opcionalmente sustituidos por amino, alquilamino inferior, acilamino, oxo, hidroxilo, alcoxilo inferior, tioalquilo inferior, o carboxilo que está opcionalmente esterificado o amidado; o un heterociclo aromático opcionalmente sustituido, que puede estar opcionalmente sustituido por amino, aminoalquilo inferior, acilamino, oxo, hidroxilo, alcoxilo inferior, tioalquilo inferior, ó carboxilo que está opcionalmente esterificado o amidado, ó alquilo inferior que está opcionalmente sustituido por halógeno, amino, aminoalquilo inferior, acilamino, hidroxilo, alcoxilo inferior, tioalquilo, inferior, aciloxi, alquenoílo inferior, alquilo inferior sulfinilo, alquilo inferior sulfonilo, cicloalquilsulfinilo, cicloalquilsulfonilo, hidroxiimino, alcoxiimino, carboxilo que está opcionalmente esterificado o amidado, alquenilo inferior, oxo, ciano, carbamoiloxilo, sulfamoílo que está opcionalmente sustituido por alquilo inferior, o amido que está opcionalmente sustituido por alquilo inferior, -C(NRRAND#39)=NR" (donde R, RAND#39 y R" son hidrógeno o alquilo inferior) y sus sales de adición farmacéuticamente aceptables.
CO00077957A 1999-10-15 2000-10-12 Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo CO5261604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120520 1999-10-15

Publications (1)

Publication Number Publication Date
CO5261604A1 true CO5261604A1 (es) 2003-03-31

Family

ID=8239207

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00077957A CO5261604A1 (es) 1999-10-15 2000-10-12 Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo

Country Status (35)

Country Link
US (1) US6407094B1 (es)
EP (1) EP1224174B1 (es)
JP (1) JP3857138B2 (es)
KR (1) KR100480320B1 (es)
CN (1) CN1195522C (es)
AR (1) AR026029A1 (es)
AT (1) ATE250039T1 (es)
AU (1) AU774451B2 (es)
BR (1) BR0014859A (es)
CA (1) CA2386974C (es)
CO (1) CO5261604A1 (es)
CZ (1) CZ20021653A3 (es)
DE (1) DE60005386T2 (es)
DK (1) DK1224174T3 (es)
EG (1) EG24079A (es)
ES (1) ES2204704T3 (es)
GC (1) GC0000263A (es)
HK (1) HK1051038A1 (es)
HR (1) HRP20020259A2 (es)
HU (1) HUP0203142A3 (es)
IL (2) IL148816A0 (es)
JO (1) JO2262B1 (es)
MA (1) MA26831A1 (es)
MY (1) MY125540A (es)
NO (1) NO327817B1 (es)
NZ (1) NZ517999A (es)
PE (1) PE20010681A1 (es)
PL (1) PL357418A1 (es)
PT (1) PT1224174E (es)
RU (1) RU2259360C2 (es)
SI (1) SI1224174T1 (es)
TR (1) TR200201023T2 (es)
WO (1) WO2001029011A2 (es)
YU (1) YU26202A (es)
ZA (1) ZA200202544B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201026T2 (tr) 1999-10-15 2002-08-21 F.Hoffmann-La Roche Ag Benzodiazepin türevleri
IL158021A0 (en) 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONIST I
NZ528315A (en) 2001-04-12 2005-04-29 F Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as MGLUR2 antagonists II
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
AU2003270166A1 (en) * 2002-09-10 2004-04-30 Novartis Ag Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
CA2532347C (en) * 2003-07-25 2012-03-27 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006048172A1 (en) 2004-11-05 2006-05-11 F. Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008128889A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
BRPI0817269A2 (pt) * 2007-09-26 2014-10-07 Sinai School Medicine Análogos de azacitidina e usos dos mesmos
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
US8642626B2 (en) 2010-07-29 2014-02-04 Taisho Pharmaceutical Co., Ltd. Ethinyl-pyrazole derivative
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体
WO2014064028A1 (en) 2012-10-23 2014-05-01 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of autistic disorders
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
CA2943877A1 (en) 2014-04-23 2015-10-29 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of intellectual disabilities
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
RU2702358C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов
CN114349779B (zh) * 2021-12-29 2023-09-26 智仑超纯环氧树脂(西安)有限公司 一种改性二氧化硅颗粒除氯剂及其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005109A1 (en) * 1995-07-31 1997-02-13 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂

Also Published As

Publication number Publication date
CN1195522C (zh) 2005-04-06
PE20010681A1 (es) 2001-06-28
PT1224174E (pt) 2004-01-30
YU26202A (sh) 2004-12-31
KR20020038954A (ko) 2002-05-24
DE60005386T2 (de) 2004-06-24
JP3857138B2 (ja) 2006-12-13
MA26831A1 (fr) 2004-12-20
NZ517999A (en) 2004-07-30
ATE250039T1 (de) 2003-10-15
HRP20020259A2 (en) 2004-04-30
GC0000263A (en) 2006-11-01
HUP0203142A3 (en) 2003-03-28
CN1379765A (zh) 2002-11-13
WO2001029011A3 (en) 2001-11-08
ZA200202544B (en) 2003-09-23
NO20021690D0 (no) 2002-04-10
DE60005386D1 (de) 2003-10-23
US6407094B1 (en) 2002-06-18
JO2262B1 (en) 2004-10-07
NO20021690L (no) 2002-04-10
HUP0203142A2 (hu) 2003-02-28
EG24079A (en) 2008-05-11
EP1224174A2 (en) 2002-07-24
IL148816A (en) 2006-10-31
JP2003512359A (ja) 2003-04-02
SI1224174T1 (en) 2003-12-31
AR026029A1 (es) 2002-12-26
IL148816A0 (en) 2002-09-12
RU2259360C2 (ru) 2005-08-27
BR0014859A (pt) 2002-07-16
CA2386974A1 (en) 2001-04-26
DK1224174T3 (da) 2004-01-26
AU774451B2 (en) 2004-06-24
KR100480320B1 (ko) 2005-04-07
HK1051038A1 (en) 2003-07-18
CZ20021653A3 (cs) 2002-08-14
PL357418A1 (en) 2004-07-26
WO2001029011A2 (en) 2001-04-26
AU7910200A (en) 2001-04-30
TR200201023T2 (tr) 2002-09-23
NO327817B1 (no) 2009-09-28
MY125540A (en) 2006-08-30
CA2386974C (en) 2009-10-13
EP1224174B1 (en) 2003-09-17
ES2204704T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
CO5261604A1 (es) Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo
ES2319775T3 (es) Combinaciones para el tratamiento del vhc.
US7718769B2 (en) Tri-peptide hepatitis C serine protease inhibitors
EP2659893A3 (en) T cell regulation
JP2003501474A5 (es)
EA020527B1 (ru) Комбинации ингибиторов вируса гепатита с
FR13C0040I2 (fr) Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
AR035711A1 (es) Prodrogas 3&#39; de 2&#39;-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
BR9814256A (pt) Derivados de (benzodioxano, benzofurano ou benzopirano) tendo propriedades de relaxamento fúndico
NO20050490L (no) 2&#39;-C-metyl-3&#39;-O-L-valinester ribofuranosylcytidin for behandling av flaviviridae infeksjoner
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
AR040500A1 (es) Inhibidores de cinasas
CO5130004A1 (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas
WO2006054178A3 (en) Thin iol
EA021554B1 (ru) Органические соединения и их применение для лечения hcv инфекции
EP2994140A2 (en) Methods for treating hcv infection
DE602006017695D1 (de) Substituierte pyrrolidin-2-one, piperidin-2-one und isothiazolidin-1,1-dioxide, ihre verwendung als kv1.5 kaliumkanalblocker und pharmazeutische zubereitungen, die sie enthalten
AR035230A1 (es) Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
BR0111859A (pt) Compostos para tratamento de relaxamento prejudicado do fundo gástrico
CA3133792A1 (en) Therapeutic methods for treating hepatitis b
BR0011237A (pt) Derivados de benzodioxano, benzofurano ou benzopirano substituìdos com aminoalquila
BR0011247A (pt) Derivados (benzodioxano, benzofurano ou benzopirano) de pirrolidinila, piperidinila ou homopiperidinila substituìdos
RU2002125463A (ru) Полипептидное соединение, способы его получения, фармацевтическая композиция и способ профилактики или лечения грибковых заболеваний
CN104995179A (zh) 作为hcv抗病毒剂的n-杂芳基取代的苯胺衍生物

Legal Events

Date Code Title Description
FD Application lapsed